Menu
| Strength | 120 mg |
| NDC | 82619-102-01 |
| GTN | 382619102017 |
| OTC/Rx | RX |
| TE Code | BX |
| Ref Brand | FENOGLIDE |
| Therapeutic Class | Primary Hypercholesterolemia, Hypertriglyceridemia |
| Strength | 40 mg |
| NDC | 82619-101-01 |
| GTN | 382619101010 |
| OTC/Rx | RX |
| TE Code | BX |
| Ref Brand | FENOGLIDE |
| Therapeutic Class | Primary Hypercholesterolemia, Hypertriglyceridemia |
| Product Details | 12's Pack | 18's Pack |
|---|---|---|
| Strength | 10 mg | 10 mg |
| NDC | 82619-112-04 | 82619-112-05 |
| GTN | 382619112047 | 382619112054 |
| OTC/Rx | RX | RX |
| TE Code | AB | AB |
| Ref Brand | MAXALT | MAXALT |
| Therapeutic Class | Antimigraine | Antimigraine |
| Product Details | 12's Pack | 18's Pack |
|---|---|---|
| Strength | 5 mg | 5 mg |
| NDC | 82619-111-04 | 82619-111-05 |
| GTN | 382619111040 | 382619111057 |
| OTC/Rx | RX | RX |
| TE Code | AB | AB |
| Ref Brand | MAXALT | MAXALT |
| Therapeutic Class | Antimigraine | Antimigraine |
| Strength | 8 mg |
| NDC | 82619-114-02 |
| GTN | 382619114027 |
| OTC/Rx | RX |
| TE Code | AB |
| Ref Brand | RAPAFLO |
| Therapeutic Class | Alpha‑1 adrenergic receptor antagonist |
| Strength | 8 mg |
| NDC | 82619-114-01 |
| GTN | 382619114010 |
| OTC/Rx | RX |
| TE Code | AB |
| Ref Brand | RAPAFLO |
| Therapeutic Class | Alpha‑1 adrenergic receptor antagonist |
| Strength | 4 mg |
| NDC | 82619-113-01 |
| GTN | 382619113013 |
| OTC/Rx | RX |
| TE Code | AB |
| Ref Brand | RAPAFLO |
| Therapeutic Class | Alpha‑1 adrenergic receptor antagonist |
| Strength | 1.25 mg+ 2.5 mg |
| NDC | 82619-104-01 |
| GTN | 382629104011 |
| OTC/Rx | RX |
| TE Code | AB |
| Ref Brand | Covaryx |
| Therapeutic Class | Hormone |
| Strength | 0.625 mg + 1.25 mg |
| NDC | 82619-103-01 |
| GTN | 382619103014 |
| OTC/Rx | RX |
| TE Code | AB |
| Ref Brand | Covaryx |
| Case Qty | 12 |
| Therapeutic Class | Hormone |